Antiretroviral naive
Taking Kaletra containing regimen with suppressed viral load.
Taking an NNRTI or integrase containing regimen without prior history of use of PI for more than 2 weeks
Taking an NNRTI or integrase containing regimen with prior exposure to PI greater than 2 weeks. It must be clearly stated in the source document that PI was switched to another agent for convenience.
Taking another PI containing regimens with suppressed viral load. It must be clearly stated in source document that if another PI was used for greater than 2 weeks the regimen was switched to another agent for convenience. Subjects with prior history of PI use may be enrolled, if there is a genotype showing no resistance to Kaletra Other Inclusion criteria
Be at least 18 years of age and able to give informed consent.
Diagnosed with TB by criteria per Brazilian Ministry of Health
Have a good clinical response to TB.
Tolerating tuberculosis therapy containing rifampin for the 2 weeks prior to screening,except for persons taking protease inhibitors at time of diagnosis of TB.,. Subjects taking protease inhibitors will be screened and initiate visit 1 within 3 days of starting TB medication
HIV positive with documentation present in source document.
Have a CD4 cell count greater than 50 cells/mm3if not taking ART. Persons with cd4 < 50 may be enrolled, if it is felt that in the best interest of the patient, that enrollment in the study will allow for quicker initiation of antiretroviral therapy than referral to another treatment center.

NCT01700790_inc_T1
Condition
naive
NCT01700790_inc_T2
Drug
Antiretroviral
NCT01700790_inc_T3
Drug
Kaletra
NCT01700790_inc_T4
Measurement
viral load
NCT01700790_inc_T5
Value
suppressed
NCT01700790_inc_T6
Drug
NNRTI
NCT01700790_inc_T7
Drug
integrase
NCT01700790_inc_T8
Negation
without
NCT01700790_inc_T9
Temporal
prior
NCT01700790_inc_T10
Drug
PI
NCT01700790_inc_T11
Value
for more than 2 weeks
NCT01700790_inc_T12
Procedure
regimen
NCT01700790_inc_T13
Procedure
regimen
NCT01700790_inc_T14
Scope
NNRTI or integrase
NCT01700790_inc_T15
Drug
NNRTI
NCT01700790_inc_T16
Drug
integrase
NCT01700790_inc_T17
Procedure
regimen
NCT01700790_inc_T18
Scope
NNRTI or integrase
NCT01700790_inc_T19
Drug
PI
NCT01700790_inc_T20
Temporal
prior
NCT01700790_inc_T21
Temporal
greater than 2 weeks
NCT01700790_inc_T22
Drug
PI
NCT01700790_inc_T23
Procedure
regimens
NCT01700790_inc_T24
Measurement
viral load
NCT01700790_inc_T25
Value
suppressed
NCT01700790_inc_T26
Value
at least 18 years
NCT01700790_inc_T27
Person
age
NCT01700790_inc_T30
Condition
TB
NCT01700790_inc_T31
Qualifier
criteria per Brazilian Ministry of Health
NCT01700790_inc_T32
Condition
good clinical response
NCT01700790_inc_T33
Condition
TB
NCT01700790_inc_T34
Condition
tuberculosis
NCT01700790_inc_T35
Procedure
tuberculosis therapy
NCT01700790_inc_T36
Drug
rifampin
NCT01700790_inc_T37
Temporal
for the 2 weeks prior to screening
NCT01700790_inc_T38
Reference_point
screening
NCT01700790_inc_T39
Drug
protease inhibitors
NCT01700790_inc_T40
Negation
except
NCT01700790_inc_T41
Temporal
at time of diagnosis of TB
NCT01700790_inc_T42
Reference_point
time of diagnosis of TB
NCT01700790_inc_T43
Measurement
HIV
NCT01700790_inc_T44
Value
positive
NCT01700790_inc_T45
Condition
HIV positive
NCT01700790_inc_T46
Measurement
CD4 cell count
NCT01700790_inc_T47
Value
greater than 50 cells/mm3
NCT01700790_inc_T48
Procedure
ART
NCT01700790_inc_T49
Negation
not
NCT01700790_inc_T50
Scope
not taking ART